



Correction to: A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent

Jennifer Hardy¹ · Stephanie Niman¹ · Rebecca F. Goldfaden¹ · Majdi Ashchi² · Mohannad Bisharat² · Jessica Huston³ · Heather Hartmann¹ · Rushab Choksi¹

©The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 / Published online: 11 December 2021

Correction to: American Journal of Cardiovascular Drugs
<https://doi.org/10.1007/s40256-021-00499-1>

In this article Fig. 2 was inadvertently published as Fig. 2a and 2b

The Fig. 2 should have appeared as shown below.
The original article has been corrected




Fig. 2 Mechanism of action of pelacarsen [20, 31]. Schematic overview of pelacarsen's mechanism of action. Pelacarsen targets LPA gene mRNA and prevents apo(a) production leading to decrease Lp(a) particle assembly.

The original article can be found online at <https://doi.org/10.1007/s40256-021-00499-1>.

✉ Rebecca F. Goldfaden
Rebecca.Goldfaden@ecirmed.com

¹ East Coast Institute for Research, Jacksonville, FL, USA

² Ashchi Heart and Vascular Center, Jacksonville, FL, USA

³ College of Pharmacy, University of Florida, Jacksonville, FL, USA